BridgeBio Pharma Inc

+0.34 (+0.62%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)8.26B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$24.34 Million
Adjusted EPS-$0.78
See more estimates
10-Day MA$56.15
50-Day MA$63.67
200-Day MA$48.68
See more pivots

BridgeBio Pharma, Inc. Stock, NASDAQ:BBIO

421 Kipling Street, Palo Alto, California 94301
United States of America
Phone: +1.650.391.9740
Number of Employees: 248


BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.